Skip to Content

Hemolysis From Ceftriaxone

Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin), one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209)....
Cannot Access - We are sorry, but you cannot access the requested article.
login now
login now
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Hemolysis From Ceftriaxone
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1144
Article Code: 1144b
Date: November 25, 2002
Volume: 44
Pages: 100-101

 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.
 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.